Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

In separate trials, Takeda’s Nesina and BMS/AstraZeneca’s Onglyza demonstrated neither cardiovascular benefit nor harm in type 2 diabetics at increased risk for such events. The DPP-4 inhibitors also were not associated with increased rates of pancreatitis, which has been a safety concern for the class.


Related Content

Diabetes Drug Safety Might Be Best Assessed With Real-World Data
AstraZeneca Diabetes Combo Needs More Clinical Data, FDA Says
Empagliflozin's CV Benefit Impresses At EASD, But What Will FDA Say?
Nothing To SAVOR For Bristol/AZ From Phase IV Results
FDA’s “Early Communication” On Pancreatitis Risk For Incretin Mimetics Draws Clinician Ire
Takeda Treads Carefully With DPP-4 Late-Arrival Nesina, Plans Summer Launch


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts